CONFERENCE UPDATE:WCLC 2020

The first ever phase 3, placebo-controlled study of nivolumab in relapsed malignant mesothelioma CONFIRMed its survival benefits

ONCOLOGY
27 Feb 2021

Get access to our exclusive articles.
Related Articles

Survival benefits of neoadjuvant nivolumab chemotherapy combination in patients with resectable NSCLC regardless of PD-L1 expression maintained in 3-year exploratory analysis from the CheckMate 816 trial

Results from the phase 3 CheckMate 816 study had found that neoadjuvant nivolumab plus chemotherapy (CTx) induced clinically significant and sustained benefits in the event-free survival (EFS) and overall survival (OS) of patients with resectable non-small cell lung cancer (NSCLC) comp
ONCOLOGY
29 Dec 2023

Adjuvant nivolumab shows effectiveness in reducing recurrence and death in patients with stage IIB/C melanoma

Data from the phase 3 CheckMate-76K trial found that adjuvant nivolumab was effective in improving recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) among patients with completely resected stage IIB/C melanoma.1 These findings supported the use of nivolumab in adjuvant setting to prevent disease recurrence of stage IIB/C melanoma.1
ONCOLOGY
31 Oct 2022

Frontline pembrolizumab plus chemotherapy significantly improves survival compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer
ONCOLOGY
30 Dec 2020

CheckMate-649 study attains superior gastric and esophageal cancer survival benefit with frontline nivolumab-chemotherapy combo
ONCOLOGY
27 Dec 2020

Nivolumab plus ipilimumab nearly doubling the response rates for women with recurrent/persistent ovarian cancer compared to nivolumab monotherapy

Despite an 80% overall response rate to primary platinum-based chemotherapy, a high proportion of women experience disease recurrence.1 At present, there is no known gold standard for the secondā€line treatment of ovarian cancer.

ONCOLOGY
30 Jun 2020